Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) announces that Pharming’s management will participate in the following investor conferences in the U.S. in the month of September:

Pharming Group N.V. (“Pharming” or “the Company”) (Euronext: PHARM/Nasdaq: PHAR) announces it will hold an Extraordinary General Meeting of Shareholders (EGM) on Monday, September 25, 2023 at 14:00 CEST. The Notice to Convene, Explanatory Notes, Voting information, meeting documents and Form of Proxy can be found on the Company’s website under Investors/Shareholder Meetings.

Pharming Group N.V. (“Pharming” or “the Company”) (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) announces that the first patient has been enrolled in its Phase III clinical trial in Japan evaluating leniolisib for the treatment of activated phosphoinositide 3-kinase delta syndrome (APDS) in adult and pediatric patients 12 years of age and older.

Pharming Group N.V. (“Pharming” or “the Company”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) presents its preliminary (unaudited) financial report for the second quarter and first half ended June 30, 2023.

Pharming Group N.V. (“Pharming” or “the Company”) (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) announces today that the Board of Directors has nominated Dr. Richard Peters to become Pharming’s new Chairman.

Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) confirms it will report its preliminary (unaudited) second quarter and first half 2023 financial results, for the period ended June 30, on Thursday, August 3, 2023.

Pharming Group N.V. (“Pharming” or “the Company”) (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) announces that it has entered into a definitive agreement with Novartis Pharma A.G. (“Novartis”) to sell its Rare Pediatric Disease Priority Review Voucher (PRV) to Novartis for a pre-agreed, one-time payment of approximately US$21.1 million shortly after closing.

Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) announces that Pharming’s management will attend the following investor conferences in the month of June:

Pharming Group N.V. (“Pharming” or “the Company”) (Euronext: PHARM/Nasdaq: PHAR) announces that at its Annual General Meeting of Shareholders (AGM) held today, the proposal for a specific authorization for the issuance of shares (or rights to acquire shares) to finance mergers, acquisitions, or strategic alliances, was not put up for a vote. All other proposals were approved.

Pharming Group N.V. (“Pharming” or “the Company”) (Euronext: PHARM/Nasdaq: PHAR) presents its preliminary, unaudited financial report for the first quarter ended March 31, 2023.

It hasn’t been the best quarter for Pharming Group N.V. ( AMS:PHARM ) shareholders, since the share price has fallen…

Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM) (Nasdaq: PHAR) announces that Pharming’s Chief Executive Officer, Sijmen de Vries will attend the H.C. Wainwright BioConnect Investor Conference 2023 on May 2, 2023 in New York and will take part in a fireside chat at 11:00 ET/17:00 CEST.

Pharming Group N.V. Sponsored ADR (PHAR) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.

Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM) (NASDAQ: PHAR) announces that Pharming’s Chief Executive Officer, Sijmen de Vries and Chief Financial Officer, Jeroen Wakkerman will attend the Van Lanschot Kempen Life Sciences Conference on April 25 and 26, 2023 in Amsterdam, the Netherlands.

Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM) (Nasdaq: PHAR) confirms it will announce first quarter 2023 financial results for the month ended March 31, 2023 on Thursday, May 11, 2023.

Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM) (Nasdaq: PHAR) announces that Pharming’s management will attend the 22nd Annual Needham Virtual Healthcare Conference April 17 – 20, 2023.

Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM) (Nasdaq: PHAR) announces the first commercial shipments of Joenja® (leniolisib) to patients in the United States. Joenja®, an oral, selective PI3Kδ inhibitor, is the first and only treatment approved in the U.S. for activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS), a rare and progressive primary immunodeficiency, in adult and pediatric patients 12 years of age and older.

Pharming Group N.V. (“Pharming” or “the Company”) (Euronext: PHARM) (Nasdaq: PHAR) announces that the Company’s 2023 Annual General Meeting of Shareholders (AGM) will be held on Wednesday, May 17, 2023, at 14:00 CEST. The Notice to Convene, Explanatory Notes, Voting information, meeting documents and Form of Proxy can be found on the Company’s website under Investors/Shareholder Meetings.

Pharming Group N.V. (“Pharming” or “the Company”) ( Euronext: PHARM / Nasdaq: PHAR) announces the filing of its Annual Report for the year ended December 31, 2022 (the “Period”). The Annual Report is available under the Financial Documents section of the Pharming website.

Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) announces that Pharming’s Chief Executive Officer, Sijmen de Vries, and Chief Commercial Officer, Stephen Toor, will attend the Guggenheim Healthcare Talks | Genomic Medicines and Rare Disease Days, April 3 – 4, 2023 in New York.